Answer
Evinacumab, a human monoclonal IgG4 antibody, is expected to be degraded into small peptides and amino acids through catabolic pathways like endogenous IgG; specific metabolism studies were not conducted because it is a protein.
Sources for this answer
- Evkeeza 150 mg/ml concentrate for solution for infusionUltragenyx UK · emc · SmPC §5.2 Pharmacokinetic properties · Version 4Document updated
Sources checked